EyePoint Pharmaceuticals, Inc. (EYPT) 10-Year Financial Performance & Capital Metrics

EYPT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Show more

Revenue $43M -6.0%
EBITDA -$144M -93.4%
Net Income -$131M -84.9%
EPS (Diluted) -2.32 -27.5%
Gross Margin 91.42% +1.7%
EBITDA Margin -333.5% -105.7%
Operating Margin -337.06% -106.6%
Net Margin -302.43% -96.6%
ROE -43.42% -11.2%
ROIC -88% +71.0%
Debt/Equity 0.06 +252.6%
Interest Coverage -10418.14 -17206.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)
✓Strong 5Y sales CAGR of 16.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 44.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y28.69%

5Y16.27%

3Y5.42%

TTM-7.38%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-98.66%

EPS CAGR

10Y-

5Y-

3Y-

TTM-49.5%

ROCE

10Y Avg-53.33%

5Y Avg-43.79%

3Y Avg-43.36%

Latest-44.11%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	26.57M	1.62M	7.54M	2.96M	20.36M	34.44M	36.94M	41.4M	46.02M	43.27M
Revenue Growth %	6.65%	-0.94%	3.65%	-0.61%	5.88%	0.69%	0.07%	0.12%	0.11%	-0.06%
Cost of Goods Sold+	14.38M	815K	0	18.5M	2.69M	5.82M	8.18M	8.33M	4.63M	3.71M
COGS % of Revenue	0.54%	0.5%	-	6.25%	0.13%	0.17%	0.22%	0.2%	0.1%	0.09%
Gross Profit+	12.18M	805K	7.54M	-15.54M	17.68M	28.61M	28.76M	33.08M	41.39M	39.56M
Gross Margin %	0.46%	0.5%	1%	-5.25%	0.87%	0.83%	0.78%	0.8%	0.9%	0.91%
Gross Profit Growth %	2.59%	-0.93%	8.37%	-3.06%	2.14%	0.62%	0.01%	0.15%	0.25%	-0.04%
Operating Expenses+	20.14M	23.39M	26.11M	29.23M	65.54M	65.9M	84.04M	132.72M	116.45M	185.41M
OpEx % of Revenue	0.76%	14.44%	3.46%	9.87%	3.22%	1.91%	2.28%	3.21%	2.53%	4.28%
Selling, General & Admin	8.06M	9.01M	11.23M	13.06M	47.71M	46.02M	53.08M	60.32M	51.79M	52.49M
SG&A % of Revenue	0.3%	5.56%	1.49%	4.41%	2.34%	1.34%	1.44%	1.46%	1.13%	1.21%
Research & Development	12.09M	14.38M	14.88M	16.18M	15.37M	17.42M	28.5M	49.64M	64.66M	132.93M
R&D % of Revenue	0.46%	8.88%	1.97%	5.46%	0.75%	0.51%	0.77%	1.2%	1.41%	3.07%
Other Operating Expenses	3K	13.98M	0	14.84M	2.46M	2.46M	2.46M	22.75M	0	0
Operating Income+	6.42M	-21.77M	-18.58M	-26.27M	-47.86M	-37.29M	-55.28M	-99.64M	-75.07M	-145.85M
Operating Margin %	0.24%	-13.44%	-2.46%	-8.87%	-2.35%	-1.08%	-1.5%	-2.41%	-1.63%	-3.37%
Operating Income Growth %	1.48%	-4.39%	0.15%	-0.41%	-0.82%	0.22%	-0.48%	-0.8%	0.25%	-0.94%
EBITDA+	7.3M	-20.96M	-17.76M	-23.62M	-45.26M	-34.64M	-52.51M	-97.19M	-74.6M	-144.31M
EBITDA Margin %	0.27%	-12.94%	-2.36%	-7.98%	-2.22%	-1.01%	-1.42%	-2.35%	-1.62%	-3.33%
EBITDA Growth %	1.58%	-3.87%	0.15%	-0.33%	-0.92%	0.23%	-0.52%	-0.85%	0.23%	-0.93%
D&A (Non-Cash Add-back)	882K	815K	815K	2.65M	2.6M	2.65M	2.77M	2.45M	464K	1.54M
EBIT	-21.7M	-18.48M	-52.45M	-39.02M	-50.62M	-38.14M	-52.92M	-99.06M	-69.47M	-130.77M
Net Interest Income+	72K	91K	-619K	-619K	-5.12M	-7.2M	-5.21M	-1.06M	5.7M	15.07M
Interest Income	72K	91K	91K	101K	1.05M	58K	292K	2.13M	6.95M	15.09M
Interest Expense	0	0	720K	720K	6.18M	7.26M	5.5M	3.19M	1.25M	14K
Other Income/Expense	72K	91K	-26.9M	-63.17M	-8.93M	-8.1M	-3.14M	-2.62M	4.36M	15.07M
Pretax Income+	6.44M	-21.7M	-18.48M	-53.17M	-56.79M	-45.39M	-58.42M	-102.25M	-70.71M	-130.78M
Pretax Margin %	0.24%	-13.4%	-2.45%	-17.96%	-2.79%	-1.32%	-1.58%	-2.47%	-1.54%	-3.02%
Income Tax+	96K	-155K	-815K	-25.56M	0	0	0	0	83K	90K
Effective Tax Rate %	0.99%	0.99%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	6.35M	-21.55M	-18.48M	-53.17M	-56.79M	-45.39M	-58.42M	-102.25M	-70.8M	-130.87M
Net Margin %	0.24%	-13.3%	-2.45%	-17.96%	-2.79%	-1.32%	-1.58%	-2.47%	-1.54%	-3.02%
Net Income Growth %	1.48%	-4.39%	0.14%	-1.88%	-0.07%	0.2%	-0.29%	-0.75%	0.31%	-0.85%
Net Income (Continuing)	-21.55M	-18.48M	-53.17M	-89.44M	-56.79M	-45.39M	-58.42M	-102.25M	-70.8M	-130.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.08	-6.81	-5.23	-11.50	-6.04	-3.54	-2.03	-2.74	-1.82	-2.32
EPS Growth %	1.43%	-4.27%	0.23%	-1.2%	0.47%	0.41%	0.43%	-0.35%	0.34%	-0.27%
EPS (Basic)	2.16	-6.81	-5.23	-11.50	-6.04	-3.54	-2.03	-2.74	-1.82	-2.32
Diluted Shares Outstanding	3.06M	3.16M	3.53M	4.62M	10.43M	12.84M	28.76M	37.32M	38.9M	56.3M
Basic Shares Outstanding	2.94M	3.16M	3.53M	4.62M	10.43M	12.84M	28.76M	37.32M	38.9M	56.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.84M	29.96M	17.74M	39.91M	41.72M	63.12M	237.75M	172.81M	344.8M	383.31M
Cash & Short-Term Investments	28.54M	28.99M	16.9M	38.78M	22.21M	44.91M	211.56M	144.56M	331.05M	370.91M
Cash Only	19.12M	15.31M	16.9M	38.78M	22.21M	44.91M	178.59M	95.63M	281.26M	99.7M
Short-Term Investments	9.41M	13.68M	0	0	0	0	32.97M	48.93M	49.79M	271.21M
Accounts Receivable	488K	251K	353K	353K	11.37M	9.45M	18.35M	15.5M	805K	607K
Days Sales Outstanding	6.71	56.55	17.09	43.51	203.75	100.19	181.36	136.67	6.38	5.12
Inventory	-622K	-488K	-251K	-353K	2.14M	5.34M	3.62M	2.89M	3.91M	2.31M
Days Inventory Outstanding	-	-	-	-	290.42	334.48	161.41	126.52	307.79	226.65
Other Current Assets	0	0	0	1.13M	0	0	517K	782K	1.01M	1.41M
Total Non-Current Assets+	2.53M	1.66M	937K	31.76M	31.25M	28.6M	25.63M	7.55M	10.38M	35.16M
Property, Plant & Equipment	338K	290K	313K	253K	3.44M	3.24M	2.73M	7.4M	10.23M	29.18M
Fixed Asset Turnover	78.59x	5.59x	24.09x	11.70x	5.93x	10.63x	13.54x	5.60x	4.50x	1.48x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.93M	1.1M	364K	31.36M	27.67M	25.21M	22.75M	0	0	0
Long-Term Investments	150K	150K	0	150K	0	0	0	0	0	0
Other Non-Current Assets	266K	264K	260K	150K	150K	150K	150K	150K	150K	5.98M
Total Assets+	32.37M	31.62M	18.68M	71.67M	72.97M	91.72M	263.37M	180.36M	355.18M	418.46M
Asset Turnover	0.82x	0.05x	0.40x	0.04x	0.28x	0.38x	0.14x	0.23x	0.13x	0.10x
Asset Growth %	0.43%	-0.02%	-0.41%	2.84%	0.02%	0.26%	1.87%	-0.32%	0.97%	0.18%
Total Current Liabilities+	3.35M	5.09M	5.29M	21.66M	11.52M	14.89M	23.66M	34.54M	63.26M	49.05M
Accounts Payable	1.36M	1.02M	2.94M	2.64M	4.19M	4.81M	7.38M	5.92M	6.5M	11.72M
Days Payables Outstanding	34.59	455.02	-	52.08	569.44	301.51	329.65	259.48	512.51	1.15K
Short-Term Debt	0	0	0	0	0	0	0	10.47M	0	0
Deferred Revenue (Current)	33K	147K	50K	30K	15K	945K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.27M	2.59M	-14.61M	15M	3.26M	5.69M	7.32M	9.52M	13.28M	13.27M
Current Ratio	8.91x	5.88x	3.35x	1.84x	3.62x	4.24x	10.05x	5.00x	5.45x	7.81x
Quick Ratio	9.10x	5.98x	3.40x	1.86x	3.44x	3.88x	9.90x	4.92x	5.39x	7.77x
Cash Conversion Cycle	-	-	-	-	-75.27	133.16	13.12	3.71	-198.34	-920.75
Total Non-Current Liabilities+	5.65M	5.64M	51K	38.32M	53.12M	58.29M	55.33M	49.45M	25.6M	32.92M
Long-Term Debt	0	0	17.31M	17.31M	47.22M	37.98M	36.56M	29.31M	0	0
Capital Lease Obligations	0	0	0	0	2.9M	2.33M	1.86M	5.98M	4.91M	21.86M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	60K	51K	-17.26M	21.01M	3M	2.37M	2.35M	600K	0	205K
Total Liabilities	9M	10.74M	5.34M	59.98M	64.64M	73.18M	78.99M	83.99M	88.86M	81.96M
Total Debt+	0	0	17.31M	17.31M	50.6M	40.99M	39.2M	46.35M	4.91M	21.86M
Net Debt	-19.12M	-15.31M	411K	-21.47M	28.39M	-3.92M	-139.39M	-49.28M	-276.36M	-77.85M
Debt / Equity	-	-	1.30x	1.48x	6.07x	2.21x	0.21x	0.48x	0.02x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-2.62x	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-25.80x	-36.49x	-7.75x	-5.14x	-10.05x	-31.24x	-60.20x	-10418.14x
Total Equity+	23.37M	20.88M	13.34M	11.69M	8.33M	18.54M	184.38M	96.37M	266.32M	336.5M
Equity Growth %	0.57%	-0.11%	-0.36%	-0.12%	-0.29%	1.23%	8.94%	-0.48%	1.76%	0.26%
Book Value per Share	7.64	6.60	3.77	2.53	0.80	1.44	6.41	2.58	6.85	5.98
Total Shareholders' Equity	23.37M	20.88M	13.34M	11.69M	8.33M	18.54M	184.38M	96.37M	266.32M	336.5M
Common Stock	293.09M	312.24M	323.32M	374.84M	11K	18K	34K	34K	49K	68K
Retained Earnings	-270.67M	-292.21M	-310.82M	-363.99M	-465.29M	-510.68M	-569.1M	-671.35M	-742.15M	-873.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	945K	852K	833K	838K	840K	841K	841K	786K	864K	1.03M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	10.3M	-16.32M	-20.49M	-21.91M	-56.7M	-14.44M	-50.1M	-65M	1.88M	-126.23M
Operating CF Margin %	0.39%	-10.07%	-2.72%	-7.4%	-2.78%	-0.42%	-1.36%	-1.57%	0.04%	-2.92%
Operating CF Growth %	1.96%	-2.58%	-0.26%	-0.07%	-1.59%	0.75%	-2.47%	-0.3%	1.03%	-68.32%
Net Income	6.35M	-21.55M	-18.48M	-53.17M	-56.79M	-45.39M	-58.42M	-102.25M	-70.8M	-130.87M
Depreciation & Amortization	882K	908K	815K	1.15M	2.6M	2.65M	2.77M	2.45M	464K	1.54M
Stock-Based Compensation	2.16M	2.46M	2.7M	3.97M	4.57M	5.55M	7.45M	14.18M	12.06M	36.74M
Deferred Taxes	0	0	0	26.28M	3.81M	905K	-787K	0	83K	90K
Other Non-Cash Items	98K	87K	-5.59M	209K	1.65M	1.72M	628K	23.65M	1.18M	-5.95M
Working Capital Changes	1.01M	2.07M	318K	925K	-12.54M	20.14M	-1.74M	-3.02M	58.88M	-27.77M
Change in Receivables	-124K	116K	219K	7K	-15.3M	4.85M	-10.6M	-2.66M	14.43M	-244K
Change in Inventory	917K	1.22M	551K	-759K	-1.86M	-3.2M	1.35M	-760K	-1.55M	1.6M
Change in Payables	292K	626K	-346K	1.75M	4.6M	1.87M	8.48M	1.2M	1.52M	5.73M
Cash from Investing+	-6.73M	-4.46M	13.58M	-16.89M	-213K	-362K	-33.12M	-17.27M	-3.31M	-219.35M
Capital Expenditures	-161K	-113K	-147K	-108K	-213K	-362K	-156K	-2.15M	-3.48M	-4.05M
CapEx % of Revenue	0.01%	0.07%	0.02%	0.04%	0.01%	0.01%	0%	0.05%	0.08%	0.09%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-4.35M	13.72M	33K	0	0	0	0	558K	168K	5.95M
Cash from Financing+	235K	16.99M	8.5M	60.67M	33.86M	37.49M	216.9M	-690K	187.07M	164.02M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	490K	99K	-844K	-20.2M	3.98M	-624K	223K	-3.19M	1.41M	813K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	10.14M	-16.43M	-20.64M	-22.02M	-56.91M	-14.8M	-50.25M	-67.16M	-1.61M	-130.28M
FCF Margin %	0.38%	-10.14%	-2.74%	-7.43%	-2.79%	-0.43%	-1.36%	-1.62%	-0.03%	-3.01%
FCF Growth %	1.93%	-2.62%	-0.26%	-0.07%	-1.59%	0.74%	-2.4%	-0.34%	0.98%	-80.02%
FCF per Share	3.31	-5.20	-5.84	-4.76	-5.46	-1.15	-1.75	-1.80	-0.04	-2.31
FCF Conversion (FCF/Net Income)	1.62x	0.76x	1.11x	0.41x	1.00x	0.32x	0.86x	0.64x	-0.03x	0.96x
Interest Paid	0	0	0	0	0	0	0	2.6M	0	0
Taxes Paid	4K	0	0	0	0	0	0	600K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	33.15%	-97.39%	-108.05%	-424.98%	-567.45%	-337.87%	-57.58%	-72.84%	-39.04%	-43.42%
Return on Invested Capital (ROIC)	251.02%	-332.77%	-144.26%	-993.47%	-266.51%	-108.94%	-139.08%	-162.32%	-303.92%	-88%
Gross Margin	45.86%	49.69%	100%	-524.86%	86.81%	83.09%	77.86%	79.89%	89.93%	91.42%
Net Margin	23.89%	-1330.06%	-245.19%	-1795.71%	-278.88%	-131.82%	-158.14%	-246.97%	-153.84%	-302.43%
Debt / Equity	-	-	1.30x	1.48x	6.07x	2.21x	0.21x	0.48x	0.02x	0.06x
Interest Coverage	-	-	-25.80x	-36.49x	-7.75x	-5.14x	-10.05x	-31.24x	-60.20x	-10418.14x
FCF Conversion	1.62x	0.76x	1.11x	0.41x	1.00x	0.32x	0.86x	0.64x	-0.03x	0.96x
Revenue Growth	664.9%	-93.9%	365.37%	-60.72%	587.77%	69.1%	7.27%	12.09%	11.14%	-5.97%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
License And Collaboration Agreement	-	-	-	-	-	-	-	-	-	38.5M
License And Collaboration Agreement Growth	-	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	-	-	-	-	3.16M
Product Growth	-	-	-	-	-	-	-	-	-	-
Y U T I Q Product	-	-	-	-	-	12.05M	13.88M	16.96M	28.33M	3.1M
Y U T I Q Product Growth	-	-	-	-	-	-	15.21%	22.20%	67.04%	-89.06%
Royalty	-	-	-	-	-	-	-	-	-	1.61M
Royalty Growth	-	-	-	-	-	-	-	-	-	-
D E X Y C U Product	-	-	-	-	-	4.78M	6.95M	18.35M	11.58M	-
D E X Y C U Product Growth	-	-	-	-	-	-	45.52%	163.96%	-36.93%	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
UNITED STATES	-	26.46M	1.52M	7.44M	2.86M	19.14M	22.62M	35.99M	40.48M	42.05M
UNITED STATES Growth	-	-	-94.26%	389.41%	-61.54%	569.14%	18.18%	59.07%	12.48%	3.87%
CHINA	-	-	-	-	-	1.12M	11.71M	851K	823K	1.12M
CHINA Growth	-	-	-	-	-	-	944.87%	-92.73%	-3.29%	36.57%
U S	3.25M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

EyePoint Pharmaceuticals, Inc. (EYPT) reported $42.3M in revenue for fiscal year 2024. This represents a 753% increase from $5.0M in 2011.

EyePoint Pharmaceuticals, Inc. (EYPT) saw revenue decline by 6.0% over the past year.

EyePoint Pharmaceuticals, Inc. (EYPT) reported a net loss of $205.8M for fiscal year 2024.

Dividend & Returns

EyePoint Pharmaceuticals, Inc. (EYPT) has a return on equity (ROE) of -43.4%. Negative ROE indicates the company is unprofitable.

EyePoint Pharmaceuticals, Inc. (EYPT) had negative free cash flow of $213.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

EyePoint Pharmaceuticals, Inc. (EYPT) 10-Year Financial Performance & Capital Metrics

EYPT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $43M -6.0%
EBITDA -$144M -93.4%
Net Income -$131M -84.9%
EPS (Diluted) -2.32 -27.5%
Gross Margin 91.42% +1.7%
EBITDA Margin -333.5% -105.7%
Operating Margin -337.06% -106.6%
Net Margin -302.43% -96.6%
ROE -43.42% -11.2%
ROIC -88% +71.0%
Debt/Equity 0.06 +252.6%
Interest Coverage -10418.14 -17206.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)
✓Strong 5Y sales CAGR of 16.3%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 44.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y28.69%

5Y16.27%

3Y5.42%

TTM-7.38%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-98.66%

EPS CAGR

10Y-

5Y-

3Y-

TTM-49.5%

ROCE

10Y Avg-53.33%

5Y Avg-43.79%

3Y Avg-43.36%

Latest-44.11%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	26.57M	1.62M	7.54M	2.96M	20.36M	34.44M	36.94M	41.4M	46.02M	43.27M
Revenue Growth %	6.65%	-0.94%	3.65%	-0.61%	5.88%	0.69%	0.07%	0.12%	0.11%	-0.06%
Cost of Goods Sold+	14.38M	815K	0	18.5M	2.69M	5.82M	8.18M	8.33M	4.63M	3.71M
COGS % of Revenue	0.54%	0.5%	-	6.25%	0.13%	0.17%	0.22%	0.2%	0.1%	0.09%
Gross Profit+	12.18M	805K	7.54M	-15.54M	17.68M	28.61M	28.76M	33.08M	41.39M	39.56M
Gross Margin %	0.46%	0.5%	1%	-5.25%	0.87%	0.83%	0.78%	0.8%	0.9%	0.91%
Gross Profit Growth %	2.59%	-0.93%	8.37%	-3.06%	2.14%	0.62%	0.01%	0.15%	0.25%	-0.04%
Operating Expenses+	20.14M	23.39M	26.11M	29.23M	65.54M	65.9M	84.04M	132.72M	116.45M	185.41M
OpEx % of Revenue	0.76%	14.44%	3.46%	9.87%	3.22%	1.91%	2.28%	3.21%	2.53%	4.28%
Selling, General & Admin	8.06M	9.01M	11.23M	13.06M	47.71M	46.02M	53.08M	60.32M	51.79M	52.49M
SG&A % of Revenue	0.3%	5.56%	1.49%	4.41%	2.34%	1.34%	1.44%	1.46%	1.13%	1.21%
Research & Development	12.09M	14.38M	14.88M	16.18M	15.37M	17.42M	28.5M	49.64M	64.66M	132.93M
R&D % of Revenue	0.46%	8.88%	1.97%	5.46%	0.75%	0.51%	0.77%	1.2%	1.41%	3.07%
Other Operating Expenses	3K	13.98M	0	14.84M	2.46M	2.46M	2.46M	22.75M	0	0
Operating Income+	6.42M	-21.77M	-18.58M	-26.27M	-47.86M	-37.29M	-55.28M	-99.64M	-75.07M	-145.85M
Operating Margin %	0.24%	-13.44%	-2.46%	-8.87%	-2.35%	-1.08%	-1.5%	-2.41%	-1.63%	-3.37%
Operating Income Growth %	1.48%	-4.39%	0.15%	-0.41%	-0.82%	0.22%	-0.48%	-0.8%	0.25%	-0.94%
EBITDA+	7.3M	-20.96M	-17.76M	-23.62M	-45.26M	-34.64M	-52.51M	-97.19M	-74.6M	-144.31M
EBITDA Margin %	0.27%	-12.94%	-2.36%	-7.98%	-2.22%	-1.01%	-1.42%	-2.35%	-1.62%	-3.33%
EBITDA Growth %	1.58%	-3.87%	0.15%	-0.33%	-0.92%	0.23%	-0.52%	-0.85%	0.23%	-0.93%
D&A (Non-Cash Add-back)	882K	815K	815K	2.65M	2.6M	2.65M	2.77M	2.45M	464K	1.54M
EBIT	-21.7M	-18.48M	-52.45M	-39.02M	-50.62M	-38.14M	-52.92M	-99.06M	-69.47M	-130.77M
Net Interest Income+	72K	91K	-619K	-619K	-5.12M	-7.2M	-5.21M	-1.06M	5.7M	15.07M
Interest Income	72K	91K	91K	101K	1.05M	58K	292K	2.13M	6.95M	15.09M
Interest Expense	0	0	720K	720K	6.18M	7.26M	5.5M	3.19M	1.25M	14K
Other Income/Expense	72K	91K	-26.9M	-63.17M	-8.93M	-8.1M	-3.14M	-2.62M	4.36M	15.07M
Pretax Income+	6.44M	-21.7M	-18.48M	-53.17M	-56.79M	-45.39M	-58.42M	-102.25M	-70.71M	-130.78M
Pretax Margin %	0.24%	-13.4%	-2.45%	-17.96%	-2.79%	-1.32%	-1.58%	-2.47%	-1.54%	-3.02%
Income Tax+	96K	-155K	-815K	-25.56M	0	0	0	0	83K	90K
Effective Tax Rate %	0.99%	0.99%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	6.35M	-21.55M	-18.48M	-53.17M	-56.79M	-45.39M	-58.42M	-102.25M	-70.8M	-130.87M
Net Margin %	0.24%	-13.3%	-2.45%	-17.96%	-2.79%	-1.32%	-1.58%	-2.47%	-1.54%	-3.02%
Net Income Growth %	1.48%	-4.39%	0.14%	-1.88%	-0.07%	0.2%	-0.29%	-0.75%	0.31%	-0.85%
Net Income (Continuing)	-21.55M	-18.48M	-53.17M	-89.44M	-56.79M	-45.39M	-58.42M	-102.25M	-70.8M	-130.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.08	-6.81	-5.23	-11.50	-6.04	-3.54	-2.03	-2.74	-1.82	-2.32
EPS Growth %	1.43%	-4.27%	0.23%	-1.2%	0.47%	0.41%	0.43%	-0.35%	0.34%	-0.27%
EPS (Basic)	2.16	-6.81	-5.23	-11.50	-6.04	-3.54	-2.03	-2.74	-1.82	-2.32
Diluted Shares Outstanding	3.06M	3.16M	3.53M	4.62M	10.43M	12.84M	28.76M	37.32M	38.9M	56.3M
Basic Shares Outstanding	2.94M	3.16M	3.53M	4.62M	10.43M	12.84M	28.76M	37.32M	38.9M	56.3M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.84M	29.96M	17.74M	39.91M	41.72M	63.12M	237.75M	172.81M	344.8M	383.31M
Cash & Short-Term Investments	28.54M	28.99M	16.9M	38.78M	22.21M	44.91M	211.56M	144.56M	331.05M	370.91M
Cash Only	19.12M	15.31M	16.9M	38.78M	22.21M	44.91M	178.59M	95.63M	281.26M	99.7M
Short-Term Investments	9.41M	13.68M	0	0	0	0	32.97M	48.93M	49.79M	271.21M
Accounts Receivable	488K	251K	353K	353K	11.37M	9.45M	18.35M	15.5M	805K	607K
Days Sales Outstanding	6.71	56.55	17.09	43.51	203.75	100.19	181.36	136.67	6.38	5.12
Inventory	-622K	-488K	-251K	-353K	2.14M	5.34M	3.62M	2.89M	3.91M	2.31M
Days Inventory Outstanding	-	-	-	-	290.42	334.48	161.41	126.52	307.79	226.65
Other Current Assets	0	0	0	1.13M	0	0	517K	782K	1.01M	1.41M
Total Non-Current Assets+	2.53M	1.66M	937K	31.76M	31.25M	28.6M	25.63M	7.55M	10.38M	35.16M
Property, Plant & Equipment	338K	290K	313K	253K	3.44M	3.24M	2.73M	7.4M	10.23M	29.18M
Fixed Asset Turnover	78.59x	5.59x	24.09x	11.70x	5.93x	10.63x	13.54x	5.60x	4.50x	1.48x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.93M	1.1M	364K	31.36M	27.67M	25.21M	22.75M	0	0	0
Long-Term Investments	150K	150K	0	150K	0	0	0	0	0	0
Other Non-Current Assets	266K	264K	260K	150K	150K	150K	150K	150K	150K	5.98M
Total Assets+	32.37M	31.62M	18.68M	71.67M	72.97M	91.72M	263.37M	180.36M	355.18M	418.46M
Asset Turnover	0.82x	0.05x	0.40x	0.04x	0.28x	0.38x	0.14x	0.23x	0.13x	0.10x
Asset Growth %	0.43%	-0.02%	-0.41%	2.84%	0.02%	0.26%	1.87%	-0.32%	0.97%	0.18%
Total Current Liabilities+	3.35M	5.09M	5.29M	21.66M	11.52M	14.89M	23.66M	34.54M	63.26M	49.05M
Accounts Payable	1.36M	1.02M	2.94M	2.64M	4.19M	4.81M	7.38M	5.92M	6.5M	11.72M
Days Payables Outstanding	34.59	455.02	-	52.08	569.44	301.51	329.65	259.48	512.51	1.15K
Short-Term Debt	0	0	0	0	0	0	0	10.47M	0	0
Deferred Revenue (Current)	33K	147K	50K	30K	15K	945K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.27M	2.59M	-14.61M	15M	3.26M	5.69M	7.32M	9.52M	13.28M	13.27M
Current Ratio	8.91x	5.88x	3.35x	1.84x	3.62x	4.24x	10.05x	5.00x	5.45x	7.81x
Quick Ratio	9.10x	5.98x	3.40x	1.86x	3.44x	3.88x	9.90x	4.92x	5.39x	7.77x
Cash Conversion Cycle	-	-	-	-	-75.27	133.16	13.12	3.71	-198.34	-920.75
Total Non-Current Liabilities+	5.65M	5.64M	51K	38.32M	53.12M	58.29M	55.33M	49.45M	25.6M	32.92M
Long-Term Debt	0	0	17.31M	17.31M	47.22M	37.98M	36.56M	29.31M	0	0
Capital Lease Obligations	0	0	0	0	2.9M	2.33M	1.86M	5.98M	4.91M	21.86M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	60K	51K	-17.26M	21.01M	3M	2.37M	2.35M	600K	0	205K
Total Liabilities	9M	10.74M	5.34M	59.98M	64.64M	73.18M	78.99M	83.99M	88.86M	81.96M
Total Debt+	0	0	17.31M	17.31M	50.6M	40.99M	39.2M	46.35M	4.91M	21.86M
Net Debt	-19.12M	-15.31M	411K	-21.47M	28.39M	-3.92M	-139.39M	-49.28M	-276.36M	-77.85M
Debt / Equity	-	-	1.30x	1.48x	6.07x	2.21x	0.21x	0.48x	0.02x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-2.62x	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-25.80x	-36.49x	-7.75x	-5.14x	-10.05x	-31.24x	-60.20x	-10418.14x
Total Equity+	23.37M	20.88M	13.34M	11.69M	8.33M	18.54M	184.38M	96.37M	266.32M	336.5M
Equity Growth %	0.57%	-0.11%	-0.36%	-0.12%	-0.29%	1.23%	8.94%	-0.48%	1.76%	0.26%
Book Value per Share	7.64	6.60	3.77	2.53	0.80	1.44	6.41	2.58	6.85	5.98
Total Shareholders' Equity	23.37M	20.88M	13.34M	11.69M	8.33M	18.54M	184.38M	96.37M	266.32M	336.5M
Common Stock	293.09M	312.24M	323.32M	374.84M	11K	18K	34K	34K	49K	68K
Retained Earnings	-270.67M	-292.21M	-310.82M	-363.99M	-465.29M	-510.68M	-569.1M	-671.35M	-742.15M	-873.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	945K	852K	833K	838K	840K	841K	841K	786K	864K	1.03M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	10.3M	-16.32M	-20.49M	-21.91M	-56.7M	-14.44M	-50.1M	-65M	1.88M	-126.23M
Operating CF Margin %	0.39%	-10.07%	-2.72%	-7.4%	-2.78%	-0.42%	-1.36%	-1.57%	0.04%	-2.92%
Operating CF Growth %	1.96%	-2.58%	-0.26%	-0.07%	-1.59%	0.75%	-2.47%	-0.3%	1.03%	-68.32%
Net Income	6.35M	-21.55M	-18.48M	-53.17M	-56.79M	-45.39M	-58.42M	-102.25M	-70.8M	-130.87M
Depreciation & Amortization	882K	908K	815K	1.15M	2.6M	2.65M	2.77M	2.45M	464K	1.54M
Stock-Based Compensation	2.16M	2.46M	2.7M	3.97M	4.57M	5.55M	7.45M	14.18M	12.06M	36.74M
Deferred Taxes	0	0	0	26.28M	3.81M	905K	-787K	0	83K	90K
Other Non-Cash Items	98K	87K	-5.59M	209K	1.65M	1.72M	628K	23.65M	1.18M	-5.95M
Working Capital Changes	1.01M	2.07M	318K	925K	-12.54M	20.14M	-1.74M	-3.02M	58.88M	-27.77M
Change in Receivables	-124K	116K	219K	7K	-15.3M	4.85M	-10.6M	-2.66M	14.43M	-244K
Change in Inventory	917K	1.22M	551K	-759K	-1.86M	-3.2M	1.35M	-760K	-1.55M	1.6M
Change in Payables	292K	626K	-346K	1.75M	4.6M	1.87M	8.48M	1.2M	1.52M	5.73M
Cash from Investing+	-6.73M	-4.46M	13.58M	-16.89M	-213K	-362K	-33.12M	-17.27M	-3.31M	-219.35M
Capital Expenditures	-161K	-113K	-147K	-108K	-213K	-362K	-156K	-2.15M	-3.48M	-4.05M
CapEx % of Revenue	0.01%	0.07%	0.02%	0.04%	0.01%	0.01%	0%	0.05%	0.08%	0.09%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-4.35M	13.72M	33K	0	0	0	0	558K	168K	5.95M
Cash from Financing+	235K	16.99M	8.5M	60.67M	33.86M	37.49M	216.9M	-690K	187.07M	164.02M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	490K	99K	-844K	-20.2M	3.98M	-624K	223K	-3.19M	1.41M	813K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	10.14M	-16.43M	-20.64M	-22.02M	-56.91M	-14.8M	-50.25M	-67.16M	-1.61M	-130.28M
FCF Margin %	0.38%	-10.14%	-2.74%	-7.43%	-2.79%	-0.43%	-1.36%	-1.62%	-0.03%	-3.01%
FCF Growth %	1.93%	-2.62%	-0.26%	-0.07%	-1.59%	0.74%	-2.4%	-0.34%	0.98%	-80.02%
FCF per Share	3.31	-5.20	-5.84	-4.76	-5.46	-1.15	-1.75	-1.80	-0.04	-2.31
FCF Conversion (FCF/Net Income)	1.62x	0.76x	1.11x	0.41x	1.00x	0.32x	0.86x	0.64x	-0.03x	0.96x
Interest Paid	0	0	0	0	0	0	0	2.6M	0	0
Taxes Paid	4K	0	0	0	0	0	0	600K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	33.15%	-97.39%	-108.05%	-424.98%	-567.45%	-337.87%	-57.58%	-72.84%	-39.04%	-43.42%
Return on Invested Capital (ROIC)	251.02%	-332.77%	-144.26%	-993.47%	-266.51%	-108.94%	-139.08%	-162.32%	-303.92%	-88%
Gross Margin	45.86%	49.69%	100%	-524.86%	86.81%	83.09%	77.86%	79.89%	89.93%	91.42%
Net Margin	23.89%	-1330.06%	-245.19%	-1795.71%	-278.88%	-131.82%	-158.14%	-246.97%	-153.84%	-302.43%
Debt / Equity	-	-	1.30x	1.48x	6.07x	2.21x	0.21x	0.48x	0.02x	0.06x
Interest Coverage	-	-	-25.80x	-36.49x	-7.75x	-5.14x	-10.05x	-31.24x	-60.20x	-10418.14x
FCF Conversion	1.62x	0.76x	1.11x	0.41x	1.00x	0.32x	0.86x	0.64x	-0.03x	0.96x
Revenue Growth	664.9%	-93.9%	365.37%	-60.72%	587.77%	69.1%	7.27%	12.09%	11.14%	-5.97%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
License And Collaboration Agreement	-	-	-	-	-	-	-	-	-	38.5M
License And Collaboration Agreement Growth	-	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	-	-	-	-	3.16M
Product Growth	-	-	-	-	-	-	-	-	-	-
Y U T I Q Product	-	-	-	-	-	12.05M	13.88M	16.96M	28.33M	3.1M
Y U T I Q Product Growth	-	-	-	-	-	-	15.21%	22.20%	67.04%	-89.06%
Royalty	-	-	-	-	-	-	-	-	-	1.61M
Royalty Growth	-	-	-	-	-	-	-	-	-	-
D E X Y C U Product	-	-	-	-	-	4.78M	6.95M	18.35M	11.58M	-
D E X Y C U Product Growth	-	-	-	-	-	-	45.52%	163.96%	-36.93%	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
UNITED STATES	-	26.46M	1.52M	7.44M	2.86M	19.14M	22.62M	35.99M	40.48M	42.05M
UNITED STATES Growth	-	-	-94.26%	389.41%	-61.54%	569.14%	18.18%	59.07%	12.48%	3.87%
CHINA	-	-	-	-	-	1.12M	11.71M	851K	823K	1.12M
CHINA Growth	-	-	-	-	-	-	944.87%	-92.73%	-3.29%	36.57%
U S	3.25M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

EyePoint Pharmaceuticals, Inc. (EYPT) reported $42.3M in revenue for fiscal year 2024. This represents a 753% increase from $5.0M in 2011.

EyePoint Pharmaceuticals, Inc. (EYPT) saw revenue decline by 6.0% over the past year.

EyePoint Pharmaceuticals, Inc. (EYPT) reported a net loss of $205.8M for fiscal year 2024.

Dividend & Returns

EyePoint Pharmaceuticals, Inc. (EYPT) has a return on equity (ROE) of -43.4%. Negative ROE indicates the company is unprofitable.

EyePoint Pharmaceuticals, Inc. (EYPT) had negative free cash flow of $213.6M in fiscal year 2024, likely due to heavy capital investments.